Optimal Prophylactic Method of Venous Thromboembolism (VTE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01448746|
Recruitment Status : Active, not recruiting
First Posted : October 7, 2011
Last Update Posted : February 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Venous Thromboembolism||Drug: low molecular weight heparin||Phase 3|
Venous thromboembolism (VTE) is common and often fatal complication in patients with cancer.
Gastric cancer is the most frequent cancer in Korea.
The incidence of VTE would be increased in patients with gastric cancer, especially associated surgery.
However, the incidence and optimal prophylactic method associated with cancer surgery are not well studied in Asian patients.
Most Korean surgeon concerns regarding the increased postoperative bleeding associated with low molecular weight heparin(LMWH)prophylaxis.
The incidence and adverse event will be examined to define the optimal prophylactic method of VTE in surgical patients with gastric cancer.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||682 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||January 2016|
|Estimated Study Completion Date :||August 2017|
Experimental: intermittent pneumatic compression
another arm include intermittent pneumatic compression plus low molecular weight heparin
Drug: low molecular weight heparin
40mg 12 hours before surgery and 12 hours later surgery
- incidence of VTE [ Time Frame: up to 30 days after operation ]The incidence of VTE between mechanical method only group and mechnical plus LMWH group.
- Adverse event [ Time Frame: up to 30 days after operation ]The adverse event such as bleeding will also be compared.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01448746
|Korea, Republic of|
|Seoul St. Mary's Hospital|
|Seoul, Korea, Republic of, 137701|
|Principal Investigator:||Kyo Young Song, M.D.||The Catholic University of Korea|